Morningstar

BeOne Medicines Ltd Ordinary Shares 06160

Morningstar Rating
Unlock
Stock XHKG Rating as of
HK$212.20 −13.20 (5.86%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Brukinsa Continues to Lead and Drive BeOne Growth as the Industry's Best-In-Class Drug

Kai Wang

BeOne is an emerging Chinese biotechnology company with a global leading position in hematologic cancers, thanks to its core drug Brukinsa. Since its approval in 2019, Brukinsa’s stronger efficacy and superior safety profile have allowed BeOne to gain market share from existing drugs. We perceive Brukinsa to be the best-in-class drug treatment for chronic lymphocytic leukemia as well as other lymphoma cancers based on statistically significant results compared with its closest competitor, AbbVie's Imbruvica.

Read Analysis

Price vs Fair Value

View History
06160 is trading at a LOCK|kWCGJLB premium.
Price
HK$212.20
Fair Value
gJm
Uncertainty
LOCK|?Y xbpZ
1-Star Price
LOCK|#.$g%
5-Star Price
LOCK|?.z>
Economic Moat
LOCK|gwp
Capital Allocation
LOCK|$pq^ZT

Bulls Say, Bears Say

Bulls

Sonrotoclax studies could become instrumental in prolonging and enhancing Brukinsa's product cycle, leading to greater market share.

Bears

Drug pipeline approvals may be less successful than previously forecast.

Show More

News

View All

Trading Information

Previous Close Price
HK$225.40
Day Range
HK$208.40–212.80
52-Week Range
HK$153.00–235.60
Bid/Ask
HK$212.20 / HK$212.40
Shares Outstanding
1.48B
Market Cap
HK$311.18B
Volume/Avg
3M / 4M

Key Statistics

Price/Earnings (Normalized)
42.21
Price/Sales
6.65
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company’s main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Core
Total Number of Employees
12,000
Website
https://www.beonemedicines.com

Competitors

Valuation

View More
Metric
06160
ABBV
Price/Earnings (Normalized)
 42.2123.91
Price/Book Value
 7.69—
Price/Sales
 6.657.16
Price/Cash Flow
 30.4219.73
Price/Earnings
06160
ABBV

Financial Strength

Metric
06160
ABBV
Quick Ratio
 2.910.49
Current Ratio
 3.400.81
Interest Coverage
 62.413.89
Quick Ratio
06160
ABBV

Profitability

Metric
06160
ABBV
Return on Assets (Normalized)
 16.92%14.29%
Return on Equity (Normalized)
 30.37%—
Return on Invested Capital (Normalized)
 24.59%32.02%
Return on Assets
06160
ABBV

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|R%k$#<LOCK|#k#?W$128B
 Moderna Inc
MRNA
LOCK|qp?h!QLOCK|Hgw$76B
 Regeneron Pharmaceuticals Inc
REGN
LOCK|$kNPvnDLOCK|mv!n$76B
 argenx SE ADR
ARGX
LOCK|j?&vyWLOCK|b>$57B
 BeOne Medicines Ltd ADR
ONC
LOCK|!!lH@xLOCK|n<$41B
 Alnylam Pharmaceuticals Inc
ALNY
LOCK|<%n^tpLOCK|B%%N$29B
 Royalty Pharma PLC Class A
RPRX
LOCK|r&!@X@V!LOCK|s^C^d$25B
 BioNTech SE ADR
BNTX
LOCK|B$f>>@LOCK|dj$24B
 Incyte Corp
INCY
LOCK|^?r<SHLOCK|hQ$$23B
 Jazz Pharmaceuticals PLC
JAZZ
LOCK|R^Dw$#<LOCK|Hp%$15B

Sponsor Center